ALBRIOZA Commercial Launch
Rx only
NDC 73063-035-04
relyvrio
TM
(sodium phenylbutyrate and
taurursodiol)
for oral suspension
3 g/1 g per packet
Each packet contains 3 g sodium
phenylbutyrate (equivalent to
2630 mg phenylbutyrate) and
1 g taurursodiol.
Each packet contains 464 mg
of sodium.
Recommended Dosage: See
prescribing information.
Keep out of sight and reach
of children.
Store at 20°C to 25°C (68°F to 77°F);
excursions permitted to 15°C to
30°C (59°F to 86°F) (see USP
Controlled Room Temperature).
Protect from moisture.
Overview of Prescribing Information
Indication
Statement
Dosing and
Administration
RELYVRIO is indicated for the treatment of
amyotrophic lateral sclerosis (ALS) in adults.
Administered orally or via a feeding tube. The
recommended dosage for the first 3 weeks of
treatment is 1 packet daily, increasing to 2
packets daily starting at the beginning of week 4.
Diarrhea
Abdominal pain
Most common
adverse events
occurring with
RELYVRIO
•
•
Nausea
•
Upper respiratory infection
Preparation: Empty contents of one
packet in a cup containing 8 ounces of water.
Stir well and take (or administer) within
1 hour of preparation.
Contains 7 single-dose packets
Please see full Prescribing Information at RELYVRIO.com
AMYLYX | 9View entire presentation